肺癌和肾癌中PD-1抑制的持久反应以及对预测性生物标志物的持续探索。 - Suppr

Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

作者信息

Awad Mark M, Hammerman Peter S

机构信息

Dana-Farber Cancer Institute, Boston, MA.

Dana-Farber Cancer Institute, Boston, MA

出版信息

J Clin Oncol. 2015 Jun 20;33(18):1993-4. doi: 10.1200/JCO.2015.61.4172. Epub 2015 Apr 27.

DOI:10.1200/JCO.2015.61.4172

PMID:25918290

Abstract

摘要

相似文献

Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

J Clin Oncol. 2015 Jun 20;33(18):1993-4. doi: 10.1200/JCO.2015.61.4172. Epub 2015 Apr 27.

Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features.

Eur Urol. 2015 Nov;68(5):912-4. doi: 10.1016/j.eururo.2015.07.008. Epub 2015 Jul 18.

In focus: bevacizumab for renal cell carcinoma.

Clin Adv Hematol Oncol. 2005 Jan;3(1):68-9.

The option value of innovative treatments for non-small cell lung cancer and renal cell carcinoma.

Am J Manag Care. 2017 Oct 1;23(10):e340-e346.

Durable Responses Achieved with AM0010.

Cancer Discov. 2016 Dec;6(12):OF4. doi: 10.1158/2159-8290.CD-NB2016-125. Epub 2016 Nov 1.

Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable.

Semin Oncol. 2017 Apr;44(2):132-135. doi: 10.1053/j.seminoncol.2017.06.007. Epub 2017 Jul 13.

[Adverse effects of immune checkpoint inhibitors used to treat melanoma and other cancer].

Presse Med. 2017 Sep;46(9):808-817. doi: 10.1016/j.lpm.2017.05.032. Epub 2017 Jul 3.

Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature.

Cancer Treat Rev. 2014 Sep;40(8):951-9. doi: 10.1016/j.ctrv.2014.05.007. Epub 2014 May 27.

FDA Approves Two New Indications and Dosage Form for Pembrolizumab.

Oncology (Williston Park). 2019 May 14;33(5):186.

Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma.

Cancer Immunol Res. 2016 Jan;4(1):12-7. doi: 10.1158/2326-6066.CIR-15-0197. Epub 2015 Nov 20.

引用本文的文献

PANoptosis-based molecular subtyping and HPAN-index predicts therapeutic response and survival in hepatocellular carcinoma.

Front Immunol. 2023 Jun 15;14:1197152. doi: 10.3389/fimmu.2023.1197152. eCollection 2023.

Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma.

Front Oncol. 2022 May 16;12:749119. doi: 10.3389/fonc.2022.749119. eCollection 2022.

Retrospective analysis of the prognostic value of PD-L1 expression and F-FDG PET/CT metabolic parameters in colorectal cancer.

J Cancer. 2020 Feb 25;11(10):2864-2873. doi: 10.7150/jca.38689. eCollection 2020.

Circulating Lymphocytes, PD-L1 Expression on Tumor-infiltrating Lymphocytes, and Survival of Colorectal Cancer Patients with Different Mismatch Repair Gene Status.

J Cancer. 2019 Apr 5;10(7):1745-1754. doi: 10.7150/jca.25187. eCollection 2019.

A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Mol Oncol. 2016 Dec;10(10):1585-1594. doi: 10.1016/j.molonc.2016.09.007. Epub 2016 Oct 14.

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.

Mol Cancer. 2016 Aug 24;15(1):55. doi: 10.1186/s12943-016-0539-x.

PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.

Oncotarget. 2016 Jul 26;7(30):48360-48374. doi: 10.18632/oncotarget.10235.

Significance of Programmed Death Ligand 1 (PD-L1) Immunohistochemical Expression in Colorectal Cancer.

Mol Diagn Ther. 2016 Apr;20(2):175-81. doi: 10.1007/s40291-016-0188-1.

Immunotherapy for lung cancer.

Transl Lung Cancer Res. 2015 Dec;4(6):675-7. doi: 10.3978/j.issn.2218-6751.2015.12.07.

Opportunities and challenges in combination gene cancer therapy.

Adv Drug Deliv Rev. 2016 Mar 1;98:35-40. doi: 10.1016/j.addr.2015.12.005. Epub 2015 Dec 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献